Hyperparathyroidism in Patients With X‐Linked Hypophosphatemia
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.3992
Abstract: X‐linked hypophosphatemia (XLH) is characterized by increased activity of circulating FGF23 resulting in renal phosphate wasting and abnormal bone mineralization. Hyperparathyroidism may develop in XLH patients; however, its prevalence, pathogenesis, and clinical presentation are not… read more here.
Keywords: pth; hypercalcemic hyperparathyroidism; pth concentrations; hyperparathyroidism ... See more keywords
Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients with X-linked Hypophosphatemia.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.1950
Abstract: Burosumab is a fully human monoclonal antibody against fibroblast growth factor 23 (FGF23), which has been approved to treat X-linked hypophosphatemia (XLH) in adult and pediatric patients. The present work describes the pharmacokinetics (PK) of… read more here.
Keywords: serum; adult pediatric; pediatric patients; linked hypophosphatemia ... See more keywords
Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia.
Sign Up to like & getrecommendations! Published in 2017 at "Bone"
DOI: 10.1016/j.bone.2016.11.019
Abstract: Seven young patients with X-linked hypophosphatemia (XLH, having inactivating PHEX mutations) were discovered to accumulate osteopontin (OPN) at the sites of defective bone mineralization near osteocytes - the so-called hallmark periosteocytic (lacunar) "halos" of XLH.… read more here.
Keywords: xlh; bone; dento osseous; linked hypophosphatemia ... See more keywords
Presentation and non-surgical endodontic treatment of two patients with X-linked hypophosphatemia: a case report.
Sign Up to like & getrecommendations! Published in 2021 at "International endodontic journal"
DOI: 10.1111/iej.13520
Abstract: AIM To describe two patients with X-linked hypophosphatemia presenting with spontaneous signs of pulpal necrosis in multiple intact teeth. The presentation and management are discussed, along with the diagnostic and endodontic treatment challenges. SUMMARY Two… read more here.
Keywords: presentation; patients linked; endodontic treatment; treatment ... See more keywords
Defective Mineralization in X-Linked Hypophosphatemia Dental Pulp Cell Cultures
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Dental Research"
DOI: 10.1177/0022034517728497
Abstract: X-linked hypophosphatemia (XLH) is a skeletal disease caused by inactivating mutations in the PHEX gene. Mutated or absent PHEX protein/enzyme leads to a decreased serum phosphate level, which cause mineralization defects in the skeleton and… read more here.
Keywords: xlh; dental pulp; linked hypophosphatemia; mineralization ... See more keywords
Vibrational spectroscopic analysis of hydroxyapatite in HYP mice and individuals with X-linked hypophosphatemia
Sign Up to like & getrecommendations! Published in 2018 at "Therapeutic Advances in Chronic Disease"
DOI: 10.1177/2040622318804753
Abstract: Background: X-linked hypophosphatemia (XLH) is the most common form of familial phosphate-wasting disorders, due to an inactivating mutation in the phosphate-regulating neutral endopeptidase, X-linked gene. Persistent osteomalacia, enthesophytes, osteophytes, degenerative arthritis and dental abscesses/periodontal disease… read more here.
Keywords: hydroxyapatite; bone; linked hypophosphatemia; mice ... See more keywords
Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the Endocrine Society"
DOI: 10.1210/jendso/bvac021
Abstract: Abstract Objective Burosumab, an anti-fibroblast growth factor 23 antibody, was recently approved for the treatment of X-linked hypophosphatemia (XLH). We evaluated the safety and efficacy of burosumab in pediatric XLH patients. Methods This open-label, phase… read more here.
Keywords: burosumab pediatric; safety; efficacy burosumab; safety efficacy ... See more keywords
Whole Body, Whole Life, Whole Family: Patients’ Perspectives on X-Linked Hypophosphatemia
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the Endocrine Society"
DOI: 10.1210/jendso/bvac086
Abstract: Abstract The rare genetic disorder X-linked hypophosphatemia (XLH) is often exclusively considered to impact children, and, as such, adult patients with XLH may receive inadequate care because their symptoms are not associated with XLH. However,… read more here.
Keywords: family; xlh; whole body; body whole ... See more keywords
An Evidence-based Physical Therapy Prescription for Adults With X-linked Hypophosphatemia
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the Endocrine Society"
DOI: 10.1210/jendso/bvac094
Abstract: Abstract Context X-linked hypophosphatemia (XLH) is a rare and progressive metabolic phosphate-wasting disorder characterized by lifelong musculoskeletal comorbidities. Despite considerable physical disability, there are currently no disease-specific physical therapy (PT) recommendations for XLH designed to… read more here.
Keywords: xlh; evidence based; physical therapy; study ... See more keywords
X-linked Hypophosphatemia (XLH) Mimicking Rheumatic Disease
Sign Up to like & getrecommendations! Published in 2020 at "Internal Medicine"
DOI: 10.2169/internalmedicine.4029-19
Abstract: A 38-year-old woman, who had been genetically diagnosed with X-linked hypophosphatemia (XLH) in childhood, was referred to our hospital due to persistent back pain and bilateral heel pain. She had visited an orthopedic surgeon and… read more here.
Keywords: xlh mimicking; rheumatic disease; linked hypophosphatemia; mimicking rheumatic ... See more keywords
Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.1034580
Abstract: Given the relatively recent introduction of burosumab in the management of X-linked hypophosphatemia (XLH), there is limited real-world data to guide its use in clinical practice. As a group of European physicians experienced with burosumab… read more here.
Keywords: burosumab linked; burosumab; burosumab treatment; children adolescents ... See more keywords